H.C. Wainwright Releases a Buy Rating on uniQure NV

By Jason Carr

In a report released today, Debjit Chattopadhyay from H.C. Wainwright assigned a Buy rating to uniQure NV (NASDAQ: QURE), with a price target of $28. The company’s shares opened today at $15.50.

According to TipRanks.com, Chattopadhyay is a 1-star analyst with an average return of -0.2% and a 43.7% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Strongbridge Biopharma Plc, and Ionis Pharmaceuticals Inc.

uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $22.

The company has a one-year high of $21.35 and a one-year low of $4.72. Currently, uniQure NV has an average volume of 752K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.